<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title xml:lang="ru">Антибиотики и Химиотерапия</journal-title><trans-title-group xml:lang="en"><trans-title>Antibiot Khimioter = Antibiotics and Chemotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0235-2990</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/0235-2990-2020-65-3-4-34-38</article-id><article-id custom-type="elpub" pub-id-type="custom">antibiotics-720</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>В ПОМОЩЬ ПРАКТИКУЮЩЕМУ ВРАЧУ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>GUIDELINES FOR PRACTITIONERS</subject></subj-group></article-categories><title-group><article-title>Прокальцитониновый тест в практике ревматолога</article-title><trans-title-group xml:lang="en"><trans-title>Procalcitonin Test in Rheumatologist's Practice</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Муравьева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Muravyeva</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Муравьева Наталья Валерьевна — кандидат медицинских наук, научный сотруд­ник лаборатории коморбидных инфекций и мониторинга безопасности лекарственной терапии</p></bio><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белов</surname><given-names>Б. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Belov</surname><given-names>B. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Белов Борис Сергеевич — кандидат медицинских наук, аведующий лаборатори­ей коморбидных инфекций и мониторинга безопасности лекарственной терапии</p><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тарасова</surname><given-names>Г. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Tarasova</surname><given-names>G. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тарасова Галина Михайловна — кандидат медицинских наук, старший научный сотрудник лаборатории коморбидных инфекций и мони­торинга безопасности лекарственной терапии</p></bio><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В. А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V. A. Nasonova Scientific Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>07</day><month>06</month><year>2020</year></pub-date><volume>65</volume><issue>3-4</issue><fpage>34</fpage><lpage>38</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Муравьева Н.В., Белов Б.С., Тарасова Г.М., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Муравьева Н.В., Белов Б.С., Тарасова Г.М.</copyright-holder><copyright-holder xml:lang="en">Muravyeva N.V., Belov B.S., Tarasova G.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.antibiotics-chemotherapy.ru/jour/article/view/720">https://www.antibiotics-chemotherapy.ru/jour/article/view/720</self-uri><abstract><sec><title>Цель</title><p>Цель. Оценить диагностическую значимость прокальцитонинового теста (ПКТ) в практике ревматолога.</p></sec><sec><title>Материал и ме­тоды</title><p>Материал и ме­тоды. В исследование включено 360 больных различными иммуновоспалительными ревматическими заболеваниями (ИВРЗ). Концентрацию ПКТ в сыворотке крови определяли количественным электрохемилюминесцентным методом на анализаторе Cobas E 411 (Roshe, Швейцария).</p></sec><sec><title>Результаты</title><p>Результаты. У больных без инфекции (n=191) медиана (Ме) уровня ПКТ составила 0,11 нг/мл [0,05; 0,16]. У больных с генерализованной инфекцией (n=11) Ме уровня ПКТ составила 3,6 нг/мл [0,88; 11,3]. При тяжёлой локальной инфекции (n=75) Ме ПКТ составила 0,45 нг/мл [0,24; 1,2], при лёгкой (n=83) — 0,12 нг/мл [0,05; 0,17]. По данным ROC-анализа, диагностическая значимость определения ПКТ при генерализованной инфекции отличная, при тяжёлой локальной инфекции — очень хорошая, при дифференциации генерализованной инфек­ции от локальной — очень хорошая.</p></sec><sec><title>Заключение</title><p>Заключение. ПКТ является ценным диагностическим тестом, способствующим рас­познаванию генерализованных и тяжёлых локальных инфекций у больных ИВРЗ. Однако при интерпретации значений ПКТ следует учитывать совокупность данных: конкретную ревматическую нозологию, результаты клинико-лабораторно­го и инструментального обследований.</p></sec></abstract><trans-abstract xml:lang="en"><p>The aim of the work is to evaluate the diagnostic significance of the procalcitonin test (PCT) in the practice of a rheumatologist.</p><sec><title>Material and methods</title><p>Material and methods. The study included 360 patients with various immuno-inflammatory rheumatic diseases (IIRD). Serum PCT concentration was determined by a quantitative electrochemiluminescent method on a Cobas E 411 analyzer (Roshe, Switzerland).</p></sec><sec><title>Results</title><p>Results. The median (Me) level of PCT was 0.11 ng/ml [0.05; 0.16] in patients without infection (n=191). In patients with generalized infection (n=11), the Me level of PCT was 3.6 ng/ml [0.88; 11.3]. In cases of severe local infection (n=75), the Me level of PCT was 0.45 ng/ml [0.24; 1,2], while in case of mild local infection (n=83) — 0.12 ng/ml [0.05; 0.17]. ROC curve analysis showed that the diagnostic significance of determining PCT for generalized infection is very high, for severe local infection it is high, and for differentiation of generalized infection from local infection it is high.</p></sec><sec><title>Conclusion</title><p>Conclusion. PCT is a valuable diagnostic test that helps recognize generalized and severe local infections in patients with IIRD. However, when interpreting the values of PCT, the totality of data should be taken into account: specific rheumatic nosology, results of clinical laboratory, and instrumental examinations.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>иммуновоспалительныеревматические заболевания</kwd><kwd>генерализованные инфекции</kwd><kwd>локальные инфекции</kwd><kwd>прокальцитониновый тест</kwd></kwd-group><kwd-group xml:lang="en"><kwd>immuno-inflammatory rheumatic diseases</kwd><kwd>generalized infections</kwd><kwd>local infections</kwd><kwd>procalcitonin test</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ромашева МЛ, Прошин Д.Г. Диагностика сепсиса у больных в критических состояниях. Общая реаниматология. — 2007. — Т. 3. — № 4. — С. 34—36.</mixed-citation><mixed-citation xml:lang="en">Romasheva M.L., Proshin D.G. Diagnosis of sepsis in critically ill patients. Obschay Reanimatologia 2007; 3 (4): 34—36 [in Russian]</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Schuetz P, Chiappa V., Briel V., Greenwald J.L. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011; 171 (15): 1322-1331.</mixed-citation><mixed-citation xml:lang="en">Schuetz P, Chiappa V., Briel V., Greenwald J.L. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011; 171 (15): 1322-1331.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Uzzan B., Cohen R., Nicolas P. et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit. Care Med 2006; 34 (7): 1996-2003.</mixed-citation><mixed-citation xml:lang="en">Uzzan B., Cohen R., Nicolas P. et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit. Care Med 2006; 34 (7): 1996-2003.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Лобань H.B., Федотова Н.Ю., Лысенко A.C. Опыт применения количественного теста на прокальцитонин для оценки эффективности антибактериальной терапии у детей первого года жизни. Вопросы диагностики в педиатрии. — 2009. — Т. 1. № 1. — С. 37-40.</mixed-citation><mixed-citation xml:lang="en">Loban N.V, Fedotova N.Yu., Lysenko A.S. Experience in using a quantitative procalcitonin test to assess the effectiveness of antibiotic therapy in infants. Vopr Diagn Pediatr 2009; 1 (1): 37-40 [in Russian]</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Becker K.L., Nylen E.S., White J.C. et al. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89 (4): 1512-1525.</mixed-citation><mixed-citation xml:lang="en">Becker K.L., Nylen E.S., White J.C. et al. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89 (4): 1512-1525.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">DahabaA.A., MetzlerH. Procalcitonin's role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator? Minerva Anestesiol 2009; 75 (7-8): 447-452.</mixed-citation><mixed-citation xml:lang="en">Dahaba A.A., Metzler H. Procalcitonin's role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator? Minerva Anestesiol 2009; 75 (7-8): 447-452.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Tavares E., Minano F.J. Immunoneutralization of the aminoprocalcitonin peptide of procalcitonin protects rats from lethal endotoxaemia: neuroendocrine and systemic studies. Clin Sci. 2010; 119 (12): 519-534. doi: 10.1042/CS20100007</mixed-citation><mixed-citation xml:lang="en">Tavares E., Minano F.J. Immunoneutralization of the aminoprocalcitonin peptide of procalcitonin protects rats from lethal endotoxaemia: neuroendocrine and systemic studies. Clin Sci. 2010; 119 (12): 519-534. doi: 10.1042/CS20100007</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Muller B., Christ-Crain M., Nylen E. et al. Limits to the use of the procalcitonin level as a diagnostic marker. Clin Infect Dis 2004; 39 (12): 1867-1868.</mixed-citation><mixed-citation xml:lang="en">Muller B., Christ-Crain M., Nylen E. et al. Limits to the use of the procalcitonin level as a diagnostic marker. Clin Infect Dis 2004; 39 (12): 1867-1868.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Meisner M. Procalcitonin. A new, innovative infection parameter. Biochemical and clinical aspects. Georg Thieme Verlag, Stuttgard-New York. 2000; 162-175.</mixed-citation><mixed-citation xml:lang="en">Meisner M. Procalcitonin. A new, innovative infection parameter. Biochemical and clinical aspects. Georg Thieme Verlag, Stuttgard-New York. 2000; 162-175.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Meisner M., Schmidt J., Huttner H., Tschaikowsky K. The natural elimination rate of procalcitonin in patients with normal and impared renal function. Intensive Care Med 2000; 26: 212-216.</mixed-citation><mixed-citation xml:lang="en">Meisner M., Schmidt J., Huttner H., Tschaikowsky K. The natural elimination rate of procalcitonin in patients with normal and impared renal function. Intensive Care Med 2000; 26: 212-216.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Shaikh M.M., Hermans L.E., van Laar J.M. Is serum procalcitonin measurement a useful addition to a rheumatologist's repertoire? A review of its diagnostic role in systemic inflammatory diseases and joint infections. Rheumatology (Oxford) 2015; 54 (2): 231-240. doi: 10.1093/rheumatol-ogy/keu416</mixed-citation><mixed-citation xml:lang="en">Shaikh M.M., Hermans L.E., van Laar J.M. Is serum procalcitonin measurement a useful addition to a rheumatologist's repertoire? A review of its diagnostic role in systemic inflammatory diseases and joint infections. Rheumatology (Oxford) 2015; 54 (2): 231-240. doi: 10.1093/rheumatol-ogy/keu416</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Meisner M. Pathobiochemistry and clinical use ofprocalcitonin. Clin Chim Acta 2002; 323 (1-2): 17-29. doi: 10.1016/S0009-9881(02)00101-8</mixed-citation><mixed-citation xml:lang="en">Meisner M. Pathobiochemistry and clinical use ofprocalcitonin. Clin Chim Acta 2002; 323 (1-2): 17-29. doi: 10.1016/S0009-9881(02)00101-8</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Вельков B.B. Прокальцитонин и С-реактивный белок в современной лабораторной диагностике. Клинико-лабораторный консилиум. — 2008. — т. 25. — № 6. — С. 46-52.</mixed-citation><mixed-citation xml:lang="en">Vel'kov V.V. Procalcitonin and C-reactive protein in modern laboratory diagnostics. Clinical laboratory Council of physicians 2008; 25 (6): 46-52. [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wu J.-Y., Shen C.-J., Hsieh Y.-C. et al. Use of serum procalcitonin to direct bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum 2012; 64 (9): 3034-3042. doi: 10.1002/art.34512</mixed-citation><mixed-citation xml:lang="en">Wu J.-Y., Shen C.-J., Hsieh Y.-C. et al. Use of serum procalcitonin to direct bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum 2012; 64 (9): 3034-3042. doi: 10.1002/art.34512</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Moosig F., Csernok E., Reinhold-Keller E. et al. Elevated procalcitonin levels in active Wegener's granulomatosis. J Rheumatol 1998; 25 (8): 1531-1533.</mixed-citation><mixed-citation xml:lang="en">Moosig F., Csernok E., Reinhold-Keller E. et al. Elevated procalcitonin levels in active Wegener's granulomatosis. J Rheumatol 1998; 25 (8): 1531-1533.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Okada Y., Minakami H., Tomomasa T. et al. Serum procalcitonin concentration infection in patients with Kawasaki disease. J Infect 2004; 48 (2): 199-205. doi: 10.1016/j.jinf.2003.08.002</mixed-citation><mixed-citation xml:lang="en">Okada Y., Minakami H., Tomomasa T. et al. Serum procalcitonin con¬centration infection in patients with Kawasaki disease. J Infect 2004; 48 (2): 199-205. doi: 10.1016/j.jinf.2003.08.002</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Scire C.A., Cavagna L., Perotti C. et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol 2006; 24 (2): 123-128.</mixed-citation><mixed-citation xml:lang="en">Scire C.A., Cavagna L., Perotti C. et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol 2006; 24 (2): 123-128.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Schwenger V., Sis J., Breitbart A., Andrassy K. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection. 1998; 26 (5): 274-276. doi: 10.1007/BF02962246</mixed-citation><mixed-citation xml:lang="en">Schwenger V., Sis J., Breitbart A., Andrassy K. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection. 1998; 26 (5): 274-276. doi: 10.1007/BF02962246</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tamaki K., Kogata Y., Sugiyama D. et al. Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol 2008; 35 (1): 114-119.</mixed-citation><mixed-citation xml:lang="en">Tamaki K., Kogata Y., Sugiyama D. et al. Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol 2008; 35 (1): 114-119.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Chen D.Y., Chen Y.M., Ho W.L. et al. Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infection inflammation in febrile patients with active adult-onset Still's disease. Ann Rheum Dis 2009; 68 (6): 1074-1075. doi: 10.1136/ard.2008.098335</mixed-citation><mixed-citation xml:lang="en">Chen D.Y., Chen Y.M., Ho W.L. et al. Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infection inflammation in febrile patients with active adult-onset Still's disease. Ann Rheum Dis 2009; 68 (6): 1074-1075. doi: 10.1136/ard.2008.098335</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Лапин C.B., Маслянский А.Л., Лазарева Н.М. и др. Значение количественного определения прокальцитонина для диагностики септических осложнений у больных аутоиммунными ревматическими заболеваниями. Клиническая лабораторная диагностика. — 2013. — № 1. — С. 28-33.</mixed-citation><mixed-citation xml:lang="en">Lapin S.V., Maslyanskiy A.L., Lazareva N.M., et al. The value of quantitative analysis of procalcitonin in diagnostics of septic complications in patients with systemic autoimmune diseases. Klinicheskaya Laboratornaya Diagnostika 2013; 1: 28-33. [in Russian]</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
